Andrew Denker - Concepedia

Concepedia

Author

Andrew Denker

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

A Denker, A. Denker, A. E. Denker, A.E. Denker, Andrew Denker, Andrew E. Denker, Annika Denker

53

Publications

1.3K

Citations

16

H-Index

49

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Alexion Pharmaceuticals (United States)Barnes-Jewish Hospital Duke Medical Center Helen Hayes Hospital

AD

About

Andrew Denker is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	786
2	Health Sciences	4	4	87
3	Biomedical Engineering	2	2	455
4	Engineering	1	1	200
5	Allergy	1	1	11

Andrew Denker

×

21

Publications

1.3K

Citations

16

H-Index

	Year	Citations
Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures Andrew Denker, Andrew R. Haas, Steven B. Nicoll, Differentiation Regenerative MedicineDevelopmental BiologyBone BiologyBone Morphogenic ProteinBone Morphogenetic Protein-2	1999	255
Formation of cartilage-like spheroids by micromass cultures of murine C3H10T1/2 cells upon treatment with transforming growth factor-β1 Andrew Denker, Steven B. Nicoll, Rocky S. Tuan Differentiation Tissue EngineeringRegenerative MedicineEngineeringGrowth Factor-β1Cartilage-like Spheroids	1995	200
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study Bente Langdahl, Neil Binkley, Henry G. Bone, Journal of Bone and Mineral Research OsteopathyGynecologyContinued TherapyPharmacotherapyContinuous Odn	2012	160
Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia Priya S. Kishnani, Cheryl R. Greenberg, Frank Rauch, Bone	2018	142
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment Gema Ariceta, Bradley P. Dixon, Seong Heon Kim, Kidney International	2020	80
Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I Leanne M. Ward, Andrew Denker, Arturo G. Porras, The Journal of Clinical Endocrinology & Metabolism	2005	65
Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates Kenneth C. Lasseter, Arturo G. Porras, Andrew Denker, Clinical Drug Investigation Molecular PharmacologyPharmacologyTerminal Elimination Half-livesPharmacotherapyMedicine	2005	62
A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study of the Calcium-Sensing Receptor Antagonist MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis Johan Halse, Susan L. Greenspan, Felicia Cosman, The Journal of Clinical Endocrinology & Metabolism	2014	42
Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia Lothar Seefried, Priya S. Kishnani, Scott Moseley, Bone	2020	37
Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, BMC Nephrology	2021	35

Page 1